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Vaccination during pregnancy is increasingly being used as an effective approach for protecting both
young infants and their mothers from serious infections. Drawing conclusions from published studies
in this area can be difficult because of the inability to compare vaccine trial results across different stud-
ies and settings due to the heterogeneity in the definitions of terms used to assess the safety of vaccines
in pregnancy and the data collected in such studies.
The guidelines proposed in this document have been developed to harmonize safety data collection
in all phases of clinical trials of vaccines in pregnant women and apply to data from the mother, fetus
and infant. Guidelines on the prioritization of the data to be collected is also provided to allow
applicability in various geographic, cultural and resource settings, including high, middle and low-
income countries.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
commons.org/licenses/by/4.0/).1. Preamble
1.1. Background and need for this guidelines
Three-quarters of all neonatal deaths worldwide occur during
the first week of life, with the first 24 h being the most critical per-
iod [1,2]. In the first months of life, transplacentally delivered
maternal antibodies are crucial for the infant’s protection against
infectious diseases. The main objective of immunization in preg-
nancy is the prevention of infections in mothers and infants at a
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from these infections. Other objectives of immunization in preg-
nancy may include reducing the severity of infections in previously
non-immune pregnant women, which, for some infections [3], can
be more severe than in non-pregnant women [4,5], as well as pre-
venting infections in the fetus [6].
Recommendations already exist in a number of countries to
vaccinate pregnant women against tetanus [7], influenza [8–11]
and pertussis [12–16], while other vaccines are recommended
where there is perceived benefit [17].
Vaccinating pregnant women is a potential strategy for prevent-
ing specific infections in infants and many vaccines are currently in
various stages of clinical trials. Examples include vaccines against
group B streptococcus (GBS) [18], respiratory syncytial virus
(RSV) [19] and Streptococcus pneumoniae [20,21].
In the United States, the National Institutes of Health have sup-
ported studies of vaccines in pregnant women since the 1980s.
Aside from a few small prospective clinical trials, most studies
have been observational because pregnancy is typically an exclu-
sion criterion for participation in research. In March 2004, the first
International Neonatal Vaccination workshop was held in Virginia
(USA) to further explore the immunology and safety of immuniza-
tion strategies to expand protection of neonates against vaccine-
preventable diseases [22]. The participants found it difficult to
draw conclusions from the studies reviewed during the workshop
because of the inability to compare vaccine trial results across dif-
ferent studies and settings, in part because critical information was
either lacking or inconsistently collected. One of the conclusions of
the workshop was that the data collected and presented from vac-
cine trials in both neonates and pregnant women should be harmo-
nized. Similarly, at an international meeting on vaccination in
pregnancy in 2012 [23], it was noted that there were no widely
accepted guidelines for data collection in studies of vaccination
in pregnancy. This lack of harmonization was also evident when
evaluating the studies conducted during the 2009–2010 H1N1
influenza pandemic, when vaccines were administered to large
numbers of pregnant women worldwide [24]. Efforts to develop
widely accepted guidelines for the assessment of safety of vaccines
in pregnant women have subsequently evolved with the recogni-
tion that immunization in pregnancy appears to be a generally safe
and effective strategy to protect both mothers and infants against
potentially life-threatening infectious diseases [25–28].
A detailed analysis of the available guidelines from regulatory
agencies and others including the Food and Drug Administration
(FDA), European Medicines Agency (EMA) and International Con-
ference on Harmonization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH) reinforced the
evidence of the lack of harmonization and the minimal guidance
available for safety monitoring (Appendix 1). The EMA has outlined
specific requirements for evaluating vaccines in pregnant women,
including: criteria to select medicinal products, including vaccines,
for which active surveillance in pregnancy is necessary, guidance
on how to monitor accidental or intended exposure to medicinal
products during pregnancy and specific requirements for reporting
and presenting data on adverse outcomes of exposure during preg-
nancy [29]. In the FDA and ICH guidelines, only general guidance
was available, but specific requirements are now emerging with
the inclusion of available data on maternal immunization in the
product labeling [30].
The guidelines proposed in this document have therefore been
developed to harmonize data collection for safety monitoring in
the course of clinical trials of vaccines in pregnant women. These
guidelines may also assist in the ongoing assessment of safety
surveillance of vaccines already recommended for use in pregnant
women, however the focus of these recommendations is data
collection in clinical trials. Guidance on the prioritization of thedata to be collected is also provided to promote collection of at
least a minimal set of high-priority parameters in various settings,
including low- and middle-income countries (LMIC).
1.2. Relationship of this guidelines to other guidelines
Internationally accepted general recommendations for the anal-
ysis and reporting of vaccine trial data already exist and should be
consulted where appropriate. These include the CONSORT state-
ment [31,32] and its extension for safety reporting in randomized
vaccine trials [33] as well as the Brighton Collaboration guidelines
for collection, analysis and presentation of vaccine safety data in
pre- and post-licensure clinical studies [34,35]. Complementary
to these general guidelines for data collection are a glossary of
terms, tables of key disease concept definitions, and standardized
case definitions for key obstetric and neonatal events for safety
monitoring of vaccines in pregnant women. These are available
on the Brighton Collaboration website (www.brightoncollabora-
tion.org). The current guidelines also build on specific guidance
documents developed for harmonizing safety assessment in trials
of vaccines in pregnant women in the United States [36–39] and
specifically aim for applicability in all resource settings.
1.3. Use of these guidelines
It was the consensus of the Brighton Collaboration Working
Group that the following guidelines are a desirable standard for
collection of vaccine safety data in clinical trials involving pregnant
women. These guidelines are intended for all parties involved in
the planning, evaluation, and implementation of relevant studies
including investigators, research networks, ethics committees
and sponsors. The ability to implement these guidelines depends
on a number of factors, such as the availability of resources, the
availability of epidemiological information, the types of vaccines
under study and the vaccine trial design.
These guidelines are intended to be applicable in diverse geo-
graphic, administrative, and cultural regions, regardless of the dif-
ferences in the availability of health care resources. The group
recognizes that implementation of all guidelines might not be pos-
sible in all settings and has therefore prioritized the collection of
data to take account of this. It is acknowledged that guidance given
the highest priority may be challenging to implement in resource-
limited settings. In these circumstances, investigators would need
to make a detailed assessment of whether sufficient resources can
be provided in order to undertake a clinical trial assessing safety of
vaccines in pregnancy. It is important to emphasize that, regardless
of the local availability of health care resources, the trial sponsor is
responsible to ensure the provision of standard care if an adverse
event does occur.
These guidelines are intended to be used alongside the comple-
mentary data collection matrix (a collection of variables to be
included in a case report form [CRF]) [40].
The proposed guidelines are not intended to guide or establish
criteria for management of ill infants, children, or adults. They are
not regulatory in nature and are not mandatory; the data collected
in individual clinical trials will be dependent on the pre-specified
aims and objectives, study setting and resources. These guidelines
are not intended to replace established or mandated processes of
adverse event reporting. The intention is to optimize and harmo-
nize the use of data obtained from participants in clinical trials.
The scientific purpose is to give added value to the reported results
of individual trials by improving data accuracy and comparability.
Additional data may be collected, analyzed, and presented as
deemed necessary by investigators, ethics committees, regulators,
and/or sponsors. Shared data collection tools and protocols should
be designed to further optimize safety reporting and to facilitate
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in this document. A directory to available tools promoting harmo-
nization is maintained at brightoncollaboration.org.
1.4. Development process of guidelines
Following the standard Brighton Collaboration process [41], a
Working Group was formed in November 2004 to develop guideli-
nes for assessment of safety in maternal and neonatal immuniza-
tion studies. This Working Group included 32 members from
developed and developing countries, with pertinent professional
backgrounds ranging from public health organizations to regula-
tory authorities, academic institutions and scientists from vaccine
manufacturers. Working Group members had expertise in immu-
nization programs, immunology, vaccine trials and regulatory
affairs, as well as obstetrics, pediatrics and infectious diseases.
The Working Group conducted regular conference calls over the
course of 2 years, elicited written comments from participants
from the 1st International Neonatal Vaccination Workshop in Vir-
ginia, and incorporated their comments. This initiative led to broad
initial guidelines considering both neonatal and maternal immu-
nization based on the contributions of the Working Group mem-
bers and other experts in the field of maternal and neonatal
immunization, as well as on a critical literature review of published
data.
In the light of increased research and regulatory activities
around immunization of pregnant women, the guidelines were
reviewed and updated again during 2012–2014. This included an
updated literature review, as well as a specific call made through
the Brighton Collaboration membership to identify any recent or
emerging guidelines. Input was also sought from experts attending
a maternal immunization consultation meeting at the World
Health Organization (WHO) in July 2014 based on the work of
two interdisciplinary Brighton Collaboration Task Forces [42]. In
the frame of the GAIA project (Global Alignment of Immunization
Safety Assessment in pregnancy; www.gaia-consortium.net), sup-
ported by the Bill & Melinda Gates Foundation, the Working Group
re-convened to derive targeted guidelines for the assessment of the
safety of vaccines in pregnant women and to finalize these guide-
lines following structured peer-review by the broad global
Brighton Collaboration Reference Group [41]. This guideline should
be considered as a ‘living document’, which will be reviewed peri-
odically and updated to take account of emerging data and feed-
back from investigators implementing these guidelines, these
will be available at www.brightoncollaboration.org.
1.4.1. The systematic literature review
The literature search was performed using English and non-
English citations for maternal and neonatal guidelines, in the con-
text of immunization, over the period from 1966 to October 2014.
The search terms used within PubMed (National Institute of
Health, US, National Library of Medicine) were: ‘‘immunization,
vaccination, neonate, neonatal, perinatal, maternal, pregnant and
pregnancy”, which led to the identification of more than 500
potentially relevant articles, which were further narrowed down
by immediate relevance for this guideline to 250 original articles
and review papers. This included the 74 studies of vaccines in preg-
nant women reviewed in depth as part of the review of the current
practice of adverse event reporting [24]. The review did not iden-
tify any publications on the standardization of data collection in
trials of vaccines in pregnant women until 2012. Since then, four
publications have become available based on the work surround-
ing vaccines in pregnant women at the U.S. National Institutes of
Health [36–39]. In addition to the peer-reviewed scientific litera-
ture, the systematic review identified the available regulatory
and other professional guidance documents (listed in Appendix 1).1.4.2. Rationale for overall structure of the guidelines
The guideline document emphasizes the following five aspects
of data collection for pregnancy vaccine trials:
(i) Clinical trial site background data collection
(ii) Pre-vaccination screening data
(iii) Vaccine- and immunization-related data
(iv) Follow-up monitoring data (including birth-related and
neonatal data)
(v) Adverse event monitoring data (including maternal, fetal
and infant)
While all outcomes of a vaccine trial in pregnancy need to be
monitored, the Working Group acknowledges that it might not
be practical to pre-define and solicit all possible clinical and labo-
ratory outcomes. However, a core dataset should be collected in all
vaccine trials in pregnancy, where feasible. Thus, each of these
main sections has been further divided into subsections based on
two priority levels for data collection:
Priority 1: Essential: data considered essential for the under-
standing of the trial results and/or required by national and/or
international regulatory authorities;
Priority 2: Complementary: data considered complementary
and important but not essential.
The Working Group emphasized the need to record essential
clinical data, in particular all evidence used to make a specific diag-
nosis. For any individual vaccine trial, additional data may be col-
lected depending on the capacities at a given vaccine trial site and
the importance of those data for the primary or secondary objec-
tives of the trial as determined by the investigators, research net-
works, ethics review committees and sponsors.
1.4.3. Specific data to be collected
Through the GAIA project a large number of clinical terms rele-
vant to trials of vaccination in pregnancy were identified. Amongst
these terms a limited number have been identified that require
standardization and a (growing) subset of these have been formally
defined [43]. Investigators are encouraged to review this list and
classify adverse events following immunization (AEFIs) according
to these case definitions. Additionally, as part of this initiative a data
collection matrix for use in clinical trial protocols (a collection of
variables to be included in a CRF) has been developed [40], as well
as an automated case classification tool [44]. Investigators are
encouraged to use these for harmonization and data comparability
purposes.
2. Guidelines
2.1. Clinical trial site background data collection: Collection of relevant
public health data on mothers and neonates
1. Specify the background rate of key maternal, fetal, neonatal
and infant conditions in the population from which trial par-
ticipants are selected or, alternatively, in a population that is
most similar to the study population. A comprehensive list of
conditions is available [43]. A recommended minimal list of
events (Priority 1) is specified below:
 Maternal and fetal conditions: rates of maternal death,
spontaneous abortion or miscarriage, stillbirth, preterm
delivery and common obstetric outcomes (cesarean sec-
tion, eclampsia/preeclampsia and preterm labor)
 Neonatal and infant conditions: rates of congenital anoma-
lies, rates of small for gestation age (SGA), low birth
weight, prematurity and neonatal death
2 Note history of drug abuse, cigarette and alcohol use in pregnancy, and all
exposures to potential teratogens that have occurred during pregnancy.
3 The interval of the medication history pre-conception and during pregnancy (note
trimester) should be based on the possible duration of acute and chronic medication
effects and relevance to the vaccine trial. This will apply particularly for medication
with a long half-life or long-term effects, such as immunoglobulins, blood transfu-
sions, or immuno-suppressants
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above data in preparation for the clinical trial.
2. Indicate the source of available background data (e.g.,
Ministry of Health or District/Provincial epidemiological data,
previous studies in comparable study settings, or observa-
tional data collected from study locality in preparation for
clinical trial) (Priority 1).
2.2. Pre-vaccination screening data
2.2.1. Maternal demographic data
This section defines data that should be collected on all partic-
ipants prior to vaccination, typically during the screening visit for
the vaccine trial.
3. Study participant identifiers (initials for the given and fam-
ily), or code, or as otherwise specified in country-specific data
protection laws (Priority 1)
4. Date of birth of pregnant woman (specify calendar used if not
Julian calendar, specify most accurate known date of birth if
actual date not known by mother [e.g., month and year])
and age at the time of screening (Priority 1)
5. The assessment of race (i.e., shared genetically determined
physical characteristics) and ethnicity (i.e., shared sociologi-
cal characteristics) should be based on locally accepted prin-
ciples, which should be summarized (Priority 1). Selected
genetic host factors, which are of potential importance for
vaccine responses (e.g., Human Leukocyte Antigen [HLA] hap-
lotypes), may transcend other descriptive means of demo-
graphic categorization, and should be assessed in such cases
(Priority 2)
6. Other demographic details, including maternal educational
level (Priority 1), household geographic location (Priority 1),
environment (urban, suburban, rural) (Priority 2) and consan-
guinity (Priority 2).
7. Surrogate indicators of socioeconomic status appropriate to
local and cultural setting (e.g., type of housing, number of
people in the home, size of home, household income, mater-
nal occupation and household assets) (Priority 2)
2.2.2. Maternal medical and obstetric history
This section defines data that should be collected and recorded
for all vaccine trial participants. Permission to review the maternal
prenatal obstetric and general medical records should be included
in the consent document.
8. General medical history, including pre-existing non-obstetric
conditions, previous surgery, and hospitalizations (Priority 1)
9. Obstetric medical history: order of the current pregnancy,
gravity, parity, attendance at antenatal visits and results of
any routine tests obtained during pregnancy to assess preg-
nancy and the fetus (e.g., congenital anomalies, ultrasound,
amniocentesis). For prior pregnancies, document dates of
delivery or termination of pregnancy, history of multiple
pregnancies, pregnancy complications, history of cesarean
section (elective or emergency), pregnancy outcome(s) (live
birth, still birth or abortion) and history of previous early-
onset neonatal infection (Priority 1)
10. Infections: results of any routine antenatal screening tests for
infections (Priority 1). Additionally, laboratory investigations
should be performed for infections that may have impact on
the immunogenicity, efficacy and safety of pregnancy vacci-
nes or aid interpretation of events that occur in the mother,
fetus, neonate or infant (Priority 1). These infections include,
but are not limited to, human immunodeficiency virus (HIV) 1and 2, malaria (where relevant), syphilis, tuberculosis (where
relevant), Zika virus (where relevant), hepatitis B virus,
rubella, hepatitis C virus, group B streptococcus, toxoplasmo-
sis, genital herpes simplex virus infections and other sexually
transmitted infections (Chlamydia, gonococcus, etc.). Addi-
tionally, background data on the target infection for specific
vaccine studies will be required (Priority 1), e.g., GBS colo-
nization and GBSuria in a subject participating in a GBS vac-
cine trial
11. Other acute non-infectious medical conditions during the
present pregnancy e.g., hematologic, including anemia, meta-
bolic, endocrine, gynecological, rheumatological, cardiovas-
cular, renal, gastrointestinal, pulmonary or neurological
conditions and any other health condition of potential impor-
tance for the immunogenicity and safety of vaccines; this
includes results of non-routine laboratory testing during
pregnancy relevant to such medical conditions (Priority 1)
12. Medication history: medication taken up to 1 month prior to
pregnancy and study vaccination, including prescription and
non-prescription drugs, herbal and homeopathic preparations
and nutritional supplements [45]. A comprehensive list of
known teratogens is available [46,47] (Priority 1) 2,3
13. History of allergies, including adverse drug reactions: allergen
and a description of the reaction
14. Vaccination history: recorded vaccines administered up to
1 year prior to enrollment and study vaccination together,
as well as date of administration (Priority 1)
2.2.3. Maternal screening examination and investigations
The following parameters should be assessed for each trial
participant:
 Nutritional status of the mother (ideally prior to and during this
pregnancy, but at enrollment as a minimum), assessed by the
most reliable, locally available methods, including measure-
ment of height and weight to establish body mass index (BMI)
or other validated nutritional indicators (Priority 1)
 Resting Heart Rate (beats per minute), systolic and diastolic
blood pressure (mmHg), respiration rate (breaths per minute),
body temperature (C or F) (Priority 1)
 Abnormalities on general physical examination
– General appearance, generalized dermatological signs, car-
diovascular signs, respiratory signs, hematological signs,
gastrointestinal signs, urogenital signs, musculoskeletal
signs, neurological signs, ocular/visual signs, endocrine/
metabolic signs (Priority 1)
 Abnormalities on obstetric examination
– Scars from previous deliveries, fundal height, documentation
of fetal heart tones and fetal movement (if applicable) (Prior-
ity 1)
 Laboratory examinations
– Full blood count, differential, Urea, Creatinine, AST⁄, ALT⁄,
GGT⁄, Bilirubin, Na, K, Cl, Glucose (⁄or equivalent according
to local laboratory) (Priority 1)
– Baseline laboratory investigations for infections that may
have impact on the immunogenicity, efficacy and safety of
pregnancy vaccines or aid interpretation of events that occur
in the mother, fetus, neonate or infant (Priority 1). These
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eficiency virus (HIV) 1 and 2, malaria (where relevant),
syphilis, tuberculosis (where relevant), Zika virus (where rel-
evant), hepatitis B virus, rubella, hepatitis C virus, GBS, tox-
oplasmosis, herpes simplex virus infections and other
sexually transmitted infections (e.g., Chlamydia, gonococ-
cus). Where relevant, the results of previous routine tests
may be used (with prior ethics approval). Additionally,
investigations relevant to the target infection for specific
vaccine studies may be required (Priority 1) (e.g., GBS colo-
nization in a subject participating in a GBS vaccine trial)
– Urine: protein, glucose, bacterial culture (Priority 2)
2.2.4. Fetal data
This section defines data that should be collected and recorded
on all vaccine trial participants.
15. Presence of fetal growth restriction (IUGR)4 (Priority 1)
16. Any fetal anomaly noted before vaccination of the mother
(e.g., by ultrasound or other screening tests [specify test])
(Priority 1)
17. Gestational age (i.e., number of weeks mother was pregnant
at the time of vaccination5) (Priority 1)
2.3. Vaccine and immunization data
18. Storage conditions of the vaccine. Study vaccines need to be
stored and managed per manufacturer and sponsor require-
ments and accountability, and appropriate storage condi-
tions must be maintained until administration of the
vaccine (Priority 1)
For all vaccine trial participants, the following information
should be collected and recorded:
19. Description of the administered vaccine(s)6: Name of the
vaccine(s), manufacturer, lot number, expiry date, actual dose
volume (Priority 1). Diluents should be described with their
lot numbers, and expiry dates (where appropriate)
20. Prior to vaccination, maternal vital signs should be obtained,
including blood pressure, heart rate, respiratory rate and
temperature (Priority 1). Vaccine should only be adminis-
tered if these parameters are within the specified normal
ranges for the study. Vaccine administration should be
deferred in women with febrile or non-febrile acute illnesses
at the time of vaccination (Priority 1)
21. Date, time and route of immunization (e.g., oral, intramuscu-
lar, intradermal, subcutaneous). This should include the ana-
tomic location of the vaccine application (Priority 1)
22. Gestational age (i.e., number of weeks mother was pregnant
at time of each dose received [see GAIA preterm birth case
definition for gestational age algorithm5]) (Priority 1)
23. Simultaneous administration of other vaccines, and their
indication (e.g., mass immunization campaign, routine vac-
cine) (Priority 1)
24. The type of healthcare provider who has immunized the par-
ticipant (e.g., physician, nurse, other) (Priority 2)4 See case definition and guidelines at brightoncollaboration.org.
5 See case definition and guidelines at brightoncollaboration.org.
6 The study protocol should specify the recommended dose, number of doses (if
part of a series of immunizations against the same disease or condition), multi or
mono-dose, pre-filled syringe and the construct and components of the vaccine
including the number and type of antigens included in the vaccine, carrier(s),
adjuvant (including adjuvant manufacturer) and preservatives used, as well as the
device type (e.g., needle, spray, micro-needle patch).2.4. Follow-up monitoring data
This section defines data that should be collected and recorded
for all vaccine trial participants.
25. Duration of follow-up to assess safety of vaccination in preg-
nancy should be predefined in the study protocol. TheWork-
ing Group recommend that the minimal follow-up time
period for safety of the mother is until 6 months after deliv-
ery or the early termination of pregnancy; the minimal
follow-up time period for the infant is 1 year after birth (Pri-
ority 1). It is recognized that there are significant logistical
challenges associated with follow-up of the infant until
1 year of age; where a shorter follow-up duration is pre-
specified, there should be adequate justification for this,
for example, based on biological characteristics of the vac-
cine, the vaccine-targeted disease or of the AEFI, including
patterns identified in previous trials. There may also be rea-
sons for extending safety follow-up further, based on the
above factors, or the characteristics of the vaccine recipient
(e.g., nutrition, underlying diseases such as immune-
depressing illnesses and other pre-existing conditions), or
the intention to assess child development and late-onset
outcomes as part of the Risk Management Plan (which
may require follow-up until 5 years of age or more).
26. Safety follow-up should include a symptom diary for a min-
imum of the first 7–14 days after each dose and regular
follow-up contacts during the first year (Priority 1) (for
example, follow-up at 1 month after each dose, at delivery,
and at 2, 6 and 12 months, depending on the trial). Some
or all of the follow-up may be in-person or through other
contact (e.g., by telephone), depending on the trial. The first
2 weeks includes recording of solicited and unsolicited acute
local and systemic AEFI. The follow-up contacts include
recording of solicited and unsolicited systemic AEFI and
any signs and symptoms indicative of vaccination failure.
2.4.1. Maternal data
This section defines data that should be collected and recorded
after vaccination for all vaccine trial participants.
27. New-onset medical conditions, surgery required, and hospi-
talizations (Priority 1)
28. Nutritional status of the mother assessed by the most reli-
able, locally available methods including measurement of
height and weight to establish BMI, or other validated nutri-
tional indicators; this should be assessed in each trimester
and at delivery (Priority 1)
29. Pregnancy monitoring: antenatal attendance, including rou-
tine tests to assess pregnancy and the fetus (e.g., tests for
congenital anomalies, ultrasound, amniocentesis) (Priority 1)
30. Infections: results of any routine antenatal screening tests
for infections (Priority 1). Additionally, the results of labora-
tory investigations for infections that may have impact on
the immunogenicity, efficacy and safety of pregnancy vacci-
nes or aid interpretation of events that occur in the mother,
fetus, neonate or infant (Priority 1). These infections include,
but are not limited to, human immunodeficiency virus (HIV)
1 and 2, malaria (where relevant), syphilis, tuberculosis
(where relevant), Zika virus (where relevant) hepatitis B
virus, rubella, hepatitis C virus, Group B streptococcus, toxo-
plasmosis, genital herpes simplex virus infections and other
sexually transmitted infections (e.g., Chlamydia, gonococ-
cus). Additionally, data on the target infection for specific
vaccine studies will be required (Priority 1) (e.g., GBS colo-
nization in subject participating in a GBS vaccine trial)
C.E. Jones et al. / Vaccine 34 (2016) 5998–6006 600331. Other acute non-infectious medical conditions during the
pregnancy (e.g., hematologic, including anemia, metabolic,
endocrine, gynecological, rheumatological, cardiovascular,
renal, gastrointestinal, pulmonary or neurological conditions
and any other health condition of potential importance for
the immunogenicity and safety of vaccines); this includes
results of non-routine laboratory testing during pregnancy
relevant to such medical conditions (Priority 1)
32. Medication history: medication received during pregnancy,
including prescription and non-prescription drugs,
immunobiological agents, herbal and homeopathic prepara-
tions and nutritional supplements [45]. A comprehensive list
of known teratogens is available [47] (Priority 1)7
33. Vaccination history: any vaccines administered since study
vaccination with date of administration (Priority 1)
2.4.2. Fetal data
This section defines data that should be collected and recorded
on all vaccine trial participants.
34. Presence of fetal growth restriction8 (IUGR) (Priority 1)
35. Any congenital anomaly noted (e.g., by ultrasound or other
tests [specify test]) (Priority 1)
2.4.3. Birth related and neonatal data
This section defines data that should be collected and recorded
for all vaccine trial participants.
36. Specify the place of delivery including geographic location
(e.g., city, country) and the setting (e.g., home, clinic, hospi-
tal) (Priority 1)
37. Specify the mode of delivery: normal spontaneous vaginal
delivery, elective versus emergency (or semi-elective),
cesarean section (Priority 1)
38. Specify presence and type of health care assistant at deliv-
ery: physician, midwife, other (Priority 2)
39. Specify length of first stage of labor, length of second stage of
labor (Priority 2)
40. Specify date and time of rupture of membranes (Priority 2)
41. Specify date and time of birth (Priority 1)
42. Perinatal maternal laboratory tests as required to assess
maternal safety (Priority 1)
43. Specify key findings of fetal monitoring during labor
(Priority 2)
44. Any medical treatment given to the mother during delivery
(e.g., antibiotic prophylaxis) (Priority 2)
45. Birth-related vitality status: live birth, stillbirth, neonatal
death8 (Priority 1)
46. Specify singleton or multiple birth (Priority 1)
47. Need for resuscitation at birth (Priority 1)
48. APGAR Score: measured at 1, 5 and 10 minutes (Priority 1)
49. Birth weight, length and head circumference (Priority 1)
50. Specify abnormalities (e.g., SGA) (Priority 1)9
51. Sex: Male, female or indeterminate (Priority 1)
52. Gestational age: Total Maturity Score (confirmation by
external physical characteristics [see GAIA preterm birth
case definition for gestational age algorithm10]) (Priority 1)
53. Nutrition: The type of feeds (e.g., breast milk
(mother/donor), formula feeding, parenteral nutrition,7 Note history of drug abuse, cigarette and alcohol use in pregnancy, and all
exposures to potential teratogens that have occurred during pregnancy.
8 See case definition and guidelines at brightoncollaboration.org.
9 See case definition and guidelines at brightoncollaboration.org.
10 See case definition and guidelines at brightoncollaboration.org.mixed feeding) and their respective start and stop times
should be recorded in months of age (Priority 2)
54. Key findings on neonatal examination (Priority 1): General
appearance (syndromic or normal), generalized dermatolog-
ical signs, cardiovascular signs, respiratory signs, hematolog-
ical signs, gastrointestinal signs, urogenital signs,
musculoskeletal signs, neurological signs (including audio-
logical test results), neurodevelopmental signs, ocular/visual
signs, endocrine/metabolic signs.
55. Presence of congenital malformations or birth injuries11
(Priority 1)
56. Presence of congenital or acute infection in the neonate12
(Priority 1)
57. Any medical or surgical treatment given to the neonate (e.g.,
antibiotic treatment, exchange transfusion, intravenous flu-
ids, steroids or other immunosuppressive therapies, herbal
remedies (Priority 1)
58. Vaccinations (and specific dates) received by the neonate
during the follow-up period (Priority 1)
59. Neonatal laboratory tests as indicated in the relevant proto-
col; should be reflective of the need for assessment of poten-
tial toxicities, and should include, at a minimum, full blood
count, differential, transaminases, bilirubin, glucose, blood
urea nitrogen and creatinine (Priority 1)
2.5. Data collection for AEFI (Priority 1)
The Working Group recommends referring to general Brighton
Collaboration guidelines and template AEFI report forms [34,35].
Data collection should be in line with the general drug safety
guidelines by the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (http://www.ich.org) and the ethical standards in
research and reporting requirements for drug adverse events by
the Council for International Organizations of Medical Sciences
(CIOMS, http://www.cioms.ch). Pertinent legally binding interna-
tional and national guidelines as well as regulatory requirements
need to be followed.
Internationally standardized terminology and case definitions
for AEFI should be used for case verification and follow-up. The
WorkingGroup recognizes andemphasizes thatAEFImaybe tempo-
rally associated with, but not necessarily caused by, administration
of a vaccine. The following guidelines outline requirements for col-
lecting high-quality information on reported AEFI, without regard
to whether there is a causal relationship to a prior immunization.
Causality assessment of individual AEFI reports should be based
on verified and well-documented cases. For the causality assess-
ment of AEFIs, investigators should consider biological plausibility
of adverse events based on safety data from pre-clinical toxicology
studies, as well as experiences with prior maternal vaccine trials
and where applicable post-licensure safety data for other maternal
vaccines [48]. Widely accepted causality assessment algorithms
should be pre-specified and followed for reporting purposes [48].
The Working Group recognizes and recommends that causality
assessment may also be done by (comparative) quantitative
analytic methods (e.g., time series) during the trial and should be
performed for AEFI regardless of individual report causality assess-
ment by investigators [48].2.5.1. Specific data collection for maternal AEFI
This section applies to the mother and is in addition to the data
collected and recorded for all mothers in Section 2.4.1.11 see case definition and guidelines at brightoncollaboration.org.
12 see case definition and guidelines at brightoncollaboration.org.
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definition for data collection for a local reaction at or near the
injection site [49]. For systemic adverse events, refer to relevant
Brighton Collaboration case definitions for appropriate guidance
on data collection [43]. For adverse events that might constitute
a clinical vaccination failure, refer to the CIOMS case definition
[50] for additional guidance on data collection.
60. Criteria fulfilled to meet a case definition and other signs or
symptoms indicative of solicited and unsolicited AEFI
61. Detailed clinical description of the event, including the qual-
ity of symptoms (e.g., type of pain)
62. Date and time of: onset, first observation, diagnosis, end of
an episode and final outcome
63. Concurrent signs, symptoms, and diseases other than the
event described
64. Recurrence of event after initial AEFI
65. Onset or occurrence of similar event prior to immunization
66. Values and units of routinely measured parameters (cm, C,
etc.) - in particular, those indicating the severity of the event
67. Method of measurement (e.g., type of thermometer, oral or
other specific route, duration of measurement)
68. Results of laboratory examinations, surgical and/or patho-
logical findings and diagnoses
69. Treatment given for the AEFI (i.e., systemic and/or local site
treatment)
70. Outcome at last observation of each AEFI should be clearly
described (e.g., recovery to pre-immunization health status,
spontaneous resolution, therapeutic intervention, persis-
tence of the event, sequelae, death, or description of any
other outcome)
71. Medical review of the event (i.e., patient seen by physician)
72. Presence or absence of concurrent local disease outbreaks or
environmental exposures pertinent to the AEFI
73. Further doses given and the outcome (i.e., re-vaccination)
2.5.2. Specific data collection for AEFI in fetus / neonate / infant born to
a vaccinated mother
This section applies to the fetus and neonate / infant born to a
mother vaccinated in pregnancy and is in addition to the data col-
lected and recorded, as specified, in Sections 2.4.2 and 2.4.3. Refer
to relevant Brighton Collaboration case definitions for appropriate
guidance on data collection [43]. For adverse events that might
constitute a clinical vaccination failure refer to general guidelines
[50] for additional guidance on data collection.
74. Criteria fulfilled to meet a case definition and other signs or
symptoms indicative of an AEFI
75. Detailed clinical description of the event including the qual-
ity of symptoms
76. Date and time of: onset, first observation, diagnosis, end of
an episode and final outcome
77. Concurrent signs, symptoms, and diseases other than the
event described
78. Values and units of routinely measured parameters (cm, C,
etc.) - in particular those indicating the severity of the event
79. Method of measurement (e.g., type of thermometer, oral or
other specific route, duration of measurement)
80. Results of laboratory examinations, surgical and/or patho-
logical findings and diagnoses
81. Treatment given for the AEFI (i.e., systemic and/or local site
treatment)
82. Outcome at last observation of each AEFI should be clearly
described (e.g., recovery to pre-immunization health status,
spontaneous resolution, therapeutic intervention,persistence of the event, sequelae, death, or description of
any other outcome)
83. Medical review of the event (i.e., patient seen by physician)
84. Presence or absence of concurrent local disease outbreaks or
relevant environmental exposures
2.5.3. Duration of follow-up after an AEFI in vaccinated mother and
neonate / infant born to a vaccinated mother
85. The duration of follow-up for AEFI should be predefined in
the protocol
86. Follow-up of reported events should be sufficient to attempt
to verify and complete the collection of information as out-
lined in the relevant sections. In particular, for all cases at
any level of diagnostic certainty and for reported events
with insufficient evidence, all signs and symptoms indicative
of the respective AEFI should be recorded
2.6. Data analysis
See Section 2.2 of the ‘‘Guidelines for collection, analysis and
presentation of vaccine safety data in pre- and post-licensure clin-
ical studies” [34].
87. Reported safety outcomes could be classified in one of the
following categories. Events that meet the AEFI case defini-
tion should be classified according to the levels of diagnostic
certainty, as specified in the relevant case definition, using
Brighton Collaboration definitions if available. Events that
do not meet the case definition at any of the levels of diag-
nostic certainty to make the diagnosis of a given AEFI could
be classified in the additional categories for analysis.
Event classification
Event meets the case definitions (Main categories)
1. Level 1 of diagnostic certainty
2. Level 2 of diagnostic certainty
3. Level 3 of diagnostic certainty
Event does not meet the case definition (Additional categories
for data analysis)
4. Reported [AEFI] with insufficient evidence to meet the case
definition
5. Not an event of [AEFI]
88. The interval between immunization and an AEFI should be
specified by using the date/time of immunization and either
the date/time of onset or first observation or diagnosis,
whichever is most appropriate for the AEFI. Whatever dates
are used, they should be used consistently within and across
study groups
89. The duration of an AEFI, if applicable, should be analyzed as
the interval between date/time of onset or first observation
or diagnosis and the end of episode or final outcome. What-
ever start and ending dates are used, they should be used
consistently within and across study groups
90. If a given AEFI occurs intermittently, the event correspond-
ing to the greatest magnitude of adverse event should be
used as the basis for categorization. Also, the frequency
and pattern of re-occurrence (e.g., periodicity) should be
analyzed
91. If more than one measurement of a particular parameter is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse event should be used as the basis
for categorization (e.g., highest body temperature during
AEFI). Analysis may also include other characteristics like
qualitative patterns of criteria defining the event (e.g., peri-
odicity, frequency, fever-days.
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data) should be analyzed in predefined increments (e.g.,
measured values, times), where applicable. When the num-
ber of cases reported is too small for stratification, the
respective values or time course should be described for
each case
93. AEFI should be analyzed by study arm and dose
94. Results obtained in subjects receiving a vaccine under study
ideally should be compared with those obtained from appro-
priately selected and documented control groups
2.7. Data presentation
See also Section 2.3 of the ‘‘Guidelines for collection, analysis
and presentation of vaccine safety data in pre- and post-licensure
clinical studies” [34].
The following guidelines represent a desirable standard for pre-
sentation or publication of analyzed AEFI data to allow comparabil-
ity in vaccine safety. They are not guidelines for primary reporting
of AEFI to a study monitor. Additional information collected and
analyzed may be presented depending on the study question and
setting. It is recommended to also refer to existing guidelines,
including CONSORT (Consolidated standards of reporting trials),
QUORUM (Improving the quality of reports ofmeta-analyses of ran-
domized controlled trials), TREND (Transparent reporting of evalu-
ations with non-randomized designs), STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) and MOOSE
(Meta-analysis of observational studies in epidemiology) for pre-
sentation and publication of randomized, controlled trials, meta-
analyses, non-randomized designs, observational studies, and
systematic reviews of vaccine safety studies, respectively [51–55].
95. Terms to describe an AEFI, such as ‘‘low-grade”, ‘‘mild”,
‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant”, are highly sub-
jective, prone to wide interpretation, and should be avoided
unless validated or clearly defined
96. Safety data should be presented with numerator and
denominator (and not only in percentages or graphical illus-
trations) and by lot or vaccine, if applicable
97. If the median and range are the appropriate statistical
descriptors, and the distribution of data is skewed, then
the mean and standard deviation should also be provided
to permit meta-analysis
98. The incidence of events meeting the case definition should
be presented and clearly identified as such in the text
99. Any publication of AEFI data should include as detailed as
possible a description of the methods used for data collec-
tion and analysis. It is essential to specify:
 the study design;
 the study group(s) including comparison group(s); e.g.,
cumulative incidence rate: 10 cases of a given AEFI
among 1 million doses administered; or incidence rates:
3 cases of a given AEFI on day 1, 2 cases on day 2, 10 cases
on day 3 following immunization, or 0 cases after the first
dose, 1 case after the second dose, 10 cases after the third
dose;
 the instrument of data collection (e.g., standardized ques-
tionnaire, diary card);
 the method, frequency, and duration of monitoring for
AEFI;
 whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 whether the date of onset and/or the date of first
observation and/or the date of diagnosis, and the end of
episode and/or final outcome were used for analysis; the data analysis plan per protocol, and the statistical
plan; and any amendments to these sections of the proto-
col added during the study;
 the trial profile, indicating participant flow during a
study, including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 Reference of the AEFI case definition used (Brighton or
other) for AEFI in the abstract or methods section of a
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